Form 4: OrbiMed Sells 1M PMV Pharma Shares

OrbiMed Advisors and OrbiMed Capital GP V LLC reported the sale of 1,000,000 shares of PMV Pharmaceuticals, Inc. common stock at $1.52 per share.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, both 10% owners and having director relationships with PMV Pharmaceuticals, Inc. (PMVP), reported a transaction.
• On October 23, 2025, 1,000,000 shares of PMV Pharmaceuticals, Inc. common stock were disposed of.
• The shares were sold at a price of $1.52 per share.
• Following this transaction, OrbiMed beneficially owns 4,975,291 shares of PMV Pharmaceuticals, Inc. common stock indirectly.
• The securities are held of record by OrbiMed Private Investments V, LP (OPI V), with OrbiMed Capital GP V LLC as its general partner and OrbiMed Advisors LLC as the managing member of GP V.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant insider sale by a major institutional investor and 10% owner. While it could be for portfolio rebalancing, it often signals a lack of conviction or a belief that the stock's upside is limited in the near term.

Negatives

• A significant sale of 1,000,000 shares by a 10% owner and director-affiliated entity, OrbiMed, could be perceived negatively by the market, signaling a potential lack of confidence or a strategic portfolio adjustment.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding PMV Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• OrbiMed Advisors LLC and OrbiMed Capital GP V LLC disclaim beneficial ownership of the securities reported for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended, except to the extent of their pecuniary interest therein, if any.
• The report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

A large insider sale by a significant institutional investor like OrbiMed, particularly one with a director relationship, can be closely watched in the biotechnology and pharmaceutical industry. Such transactions may influence market perception of the company's near-term prospects or the investor's portfolio strategy.

Related Party Transactions

• The reported transaction involves the sale of common stock by OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which are 10% owners and have director relationships with PMV Pharmaceuticals, Inc., qualifying it as a related party transaction.

Stakeholder Impact

• Shareholders may interpret the large insider sale as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might view this transaction as a cautionary sign, influencing their investment decisions regarding PMV Pharmaceuticals, Inc.

Key Dates

Recommendation

The sale of a substantial block of shares by a significant insider and 10% owner, OrbiMed, typically indicates a lack of conviction in the company's near-term prospects or a belief that the stock is fully valued. This action by a sophisticated investor suggests a cautious or negative outlook, warranting a 'sell' recommendation for other investors.

Keywords

PMV Pharmaceuticals, PMVP, OrbiMed Advisors, OrbiMed Capital, Insider Sale, Beneficial Ownership, Form 4, Equity Transaction